三阴性乳腺癌的肿瘤免疫微环境  

The immune microenvironment of triple-negative breast cancer

作　　者：顾彰琦 朱玥 刘瑾琰 钱伟峰[1] GU Zhangqi;ZHU Yue;LIU Jinyan;QIAN Weifeng(The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou 215002,China)

机构地区：[1]南京医科大学附属苏州医院,苏州215002

出　　处：《生命的化学》2025年第4期718-728,共11页Chemistry of Life

摘　　要：三阴性乳腺癌(triple negative breast cancer,TNBC)是乳腺癌中一种具有高度侵袭性且早期复发率高的亚型。由于缺乏雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)的表达,传统的内分泌治疗和靶向治疗对TNBC的治疗效果受限。近年来,关于肿瘤免疫微环境(tumor immune microenvironment,TIME)的研究迅速发展,为TNBC的治疗带来了新希望。肿瘤浸润淋巴细胞(tumor infiltrating lymphocyte,TIL)、肿瘤相关巨噬细胞(tumor-associated macrophage,TAM)以及免疫检查点抑制剂等方面的研究逐渐增多,免疫疗法在TNBC的临床治疗中展现出巨大的潜力。本文综述了TIL、TAM以及免疫疗法在TNBC研究中的最新进展,并探讨了其在临床应用中的前景和面临的挑战。Triple negative breast cancer(TNBC)is a highly aggressive subtype of breast cancer with a high rate of early recurrence.Due to the lack of estrogen receptor(ER),progesterone receptor(PR)and human epidermal growth factor receptor 2(HER2),conventional endocrine therapy and targeted therapy have limited effect in TNBC.The burgeoning field of tumor immune microenvironment(TIME)research has emerged as a promising avenue for TNBC treatment.Studies have increasingly focused on tumor-infiltrating lymphocyte(TIL),tumor-associated macrophage(TAM),and immune checkpoint inhibitors,highlighting the potential of immunotherapy in the clinical management of TNBC.This review delineates the contemporary progress in the study of TIL,TAM,and immunotherapy in TNBC,with discussion of their prospects and challenges in clinical application.

关 键 词：三阴乳腺癌 肿瘤免疫微环境 肿瘤浸润淋巴细胞 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]